1. Home
  2. AVR

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

NYSE

Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

Founded: 1999 Country:
Australia
Australia
Employees: N/A City: EAGAN
Market Cap: 241.5M IPO Year: 2024
Target Price: $16.50 AVG Volume (30 days): 273.4K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.77 EPS Growth: N/A
52 Week Low/High: $3.71 - $8.79 Next Earning Date: 05-16-2025
Revenue: $2,703,000 Revenue Growth: -1.17%
Revenue Growth (this year): 37.33% Revenue Growth (next year): 141.49%

Share on Social Networks: